Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MCLA-129 |
Trade Name | |
Synonyms | MCLA 129|MCLA129 |
Drug Descriptions |
MCLA-129 is a bispecific antibody that binds to and inhibits EGFR and MET, which may lead to inhibition of cell proliferation and tumor regression (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr LB-C07). |
DrugClasses | EGFR Inhibitor (Pan) 62 MET Antibody 31 |
CAS Registry Number | NA |
NCIT ID | C179831 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Erlotinib + MCLA-129 | Erlotinib MCLA-129 | 0 | 0 |
MCLA-129 | MCLA-129 | 0 | 1 |
MCLA-129 + Osimertinib | MCLA-129 Osimertinib | 0 | 1 |